A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Lentiviral Mediated Delivery of shRNAs to hESCs and NPCs Using Low-cost Cationic Polymer Polyethylenimine (PEI)

2.7K views

⸱

DOI:

10.3791/63953

⸱

May 24th, 2022

 , 

Corresponding Authors: Suraiya Anjum Ansari <sansari@uaeu.ac.ae>

In This Article

Summary

Using the low-cost cationic polymer polyethylenimine (PEI), we produced lentiviral particles for stable expression of shRNAs in H9 human embryonic stem cells (hESCs) and transiently transduced H9-derived neural progenitor cells (NPCs) at high efficiency.

Abstract

The current protocol describes the use of lentiviral particles for the delivery of short hairpin RNAs (shRNAs) to both human embryonic stem cells (hESCs) as well as neural progenitor cells (NPCs) derived from hESCs at high efficiency. Lentiviral particles were generated by co-transfecting HEK293T cells using entry vectors (carrying shRNAs) along with packaging plasmids (pAX and pMD2.G) using the low-cost cationic polymer polyethylenimine (PEI). Viral particles were concentrated using ultracentrifugation, which resulted in average titers above 5 x 107. Both hESCs and NPCs could be infected at high efficiencies using these lentiviral particles, as shown by puromycin selection and stable expression in hESCs, as well as transient GFP expression in NPCs. Furthermore, western blot analysis showed a significant reduction in the expression of genes targeted by shRNAs. In addition, the cells retained their pluripotency as well as differentiation potential, as evidenced by their subsequent differentiation into different lineages of CNS. The current protocol deals with the delivery of shRNAs; however, the same approach could be used for the ectopic expression of cDNAs for overexpression studies.

Introduction

Human embryonic stem cells (hESCs) derived from the blastocyst inner cell mass are pluripotent and can be differentiated into different cell types depending upon external factors under in vitro conditions1,2. In order to fully harness the potential of hESCs, it is imperative to have rapid and reliable gene delivery methods for these cells. Conventionally, the techniques used can be broadly classified into two types: nonviral and viral gene delivery systems3,4. The more frequently used nonviral gene delivery systems are lipofection, electropora....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Transfection of HEK293T cells using either PEI or Lipofectamine 3000 reagent

  1. Culture HEK293T cells in DMEM + 10% FBS + 1x penicillin/streptomycin at 37 °C in a humidified incubator with an atmosphere of 5% CO2 and 21% O2 until they are 90% confluent before seeding for transfection. Use a relatively low passage number of cells for high titer virus production (ideally less than P30).
  2. Seed 4 x 106 cells in 10 mL of complete growth medium in a 100 mm tissue culture plate and grow overnight in a humidified tissue culture incubator with an atmosphere of 5% CO2 and 21% O2.

Access restricted. Please log in or start a trial to view this content.

Results

Following gene transfer, high viability of hESCs is inevitably required. Despite the efforts and optimization of protocols to reduce cell death following electroporation of hESCs, more than 50% cell death is still observed after electroporation of these cells, along with low transfection efficiency20. Lentiviral mediated gene transfer not only results in high efficiency of gene transfer but also demonstrates high levels of cell viability following transduction. The results below present two approa.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The ability to genetically modify stem cells for study or clinical purposes is limited both by technology and the basic understanding of the biology of hESCs. Techniques that have shown significant potential in mouse ESCs, like lipofection and electroporation, are not highly efficient for hESCs, which are notoriously difficult for gene delivery by conventional methods20. This notion has led to not only the optimization of existing techniques but also the development of novel methods for increased .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that there is no conflict of interest.

Acknowledgements

This work was supported by research grants from the United Arab Emirates University (UAEU), grant # 31R170 (Zayed Center for Health Sciences) and # 12R010 (UAEU-AUA grant). We thank Prof Randall Morse (Wadsworth Center, Albany, NY) for helping us to edit the manuscript for style and grammar.

All data are available upon request.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
2-MercaptoethanolInvitrogen31350010
38.5 mL, Sterile + Certified Free Open-Top Thinwall Ultra-Clear TubesBeckman CoulterC14292
AccutaseStem Cell Technologies7920
bFGF Recombinant humanInvitrogenPHG0261
Bovine serum albumin FRAC VInvitrogen15260037
Corning Matrigel Basement Membrane Matrix, LDEV-freeCorning354234
CyclopamineStem Cell Technologies72074
DMEM mediaInvitrogen11995073
DMEM Nutrient mix F12 Invitrogen11320033
DPBS w/o: Ca and MgPAN BiotechP04-36500
Fetal bovie serumInvitrogen10270106
GAPDH (14C10) Rabbit mAb AntibodyCST2118S
Gentle Cell Dissociation ReagentStem Cell Technologies7174
HyClone Non Essential Amino Acids (NEAA) 100X SolutionGE healthcareSH30238.01
L Glutamine, 100X Invitrogen2924190090
L2HGDH Polyclonal antibodyProteintech15707-1-AP
L2HGDH shRNAMacrogenSeq: CGCATTCTTCATGTGAGAAAT
Lipofectamine 3000 kitThermo FisherL3000001
mTesR1 complete mediaStem Cell Technologies85850
Neurobasal medium 1X CTSInvitrogenA1371201
Neuropan 2 Supplement 100xPAN BiotechP07-11050
Neuropan 27 Supplement 50xPAN BiotechP07-07200
Penicillin streptomycin SOLInvitrogen15140122
pLKO.1 TRC vectorAddgene10878
pLL3.7 vector Addgene11795
pMD2.GAddgene12259
Polybrene infection reagentSigmaTR1003- G
Polyethylenimine, branchedSigma408727
psPAX2.0Addgene12260
PurmorphamineTocris4551/10
PuromycinInvitrogenA1113802
ROCK inhibitor Y-27632
dihydrochloride 
Tocris1254
SB 431542Tocris1614/10
Trypsin .05% EDTA Invitrogen25300062
XAV 939Tocris3748/10

References

  1. Thomson, J. A., et al. Embryonic stem cell lines derived from human blastocysts. Science. 282 (5391), 1145-1147 (1998).
  2. Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A., Bongso, A. Embryonic stem cell lines from human blastocysts: Somatic differentiation in....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Lentiviral DeliveryshRNA TransfectionHuman Embryonic Stem CellsNeural Progenitor CellsPolyethylenimine TransfectionHEK293T CellsUltracentrifugationViral Particle ConcentrationWestern BlotGFP Expression